By Michele Maatouk
Date: Monday 24 Aug 2026
(Sharecast News) - JPMorgan upgraded Diploma on Monday to 'overweight' from 'neutral' and hiked the price target to 8,250p from 5,760p to reflect its view that it's a high-quality compounder, capable of sustaining double-digit earnings per share growth into the medium term.
| Director/PDMR Shareholding | 20-Jul-2026 | 10:00 | RNS |
| Q3 Trading Update | 16-Jul-2026 | 07:00 | RNS |
| Change of Director responsibilities | 03-Jul-2026 | 15:05 | RNS |
| Appointment of Non-Executive Director | 01-Jun-2026 | 16:00 | RNS |
| Director/PDMR Shareholding | 21-May-2026 | 17:01 | RNS |
| Drug shares on a high | 19-Nov-2006 | Scotland on Sunday |
| Questor: Diploma | 14-May-2014 | Telegraph |
| Questor :Diploma | 17-Jan-2014 | Telegraph |
| Investment Column : Diploma | 18-May-2011 | The Independent |
| Questor:Diploma | 16-Feb-2011 | Telegraph |
| Investment Column:Diploma | 23-Nov-2010 | The Independent |
No recent information was found.
| Currency | UK Pounds |
| Share Price | 7,290.00p |
| Change Today | -65.00p |
| % Change | -0.88 % |
| 52 Week High | 7,710.00p |
| 52 Week Low | 5,015.00p |
| Volume | 650,533 |
| Shares Issued | 134.32m |
| Market Cap | £9,792m |
| RiskGrade | 165 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 5 |
| Buy | 5 |
| Neutral | 3 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 14 |

| Latest | Previous | |
|---|---|---|
| Interim | Final | |
| Ex-Div | 28-May-26 | 15-Jan-26 |
| Paid | 12-Jun-26 | 30-Jan-26 |
| Amount | 19.10p | 44.10p |
| Time | Volume / Share Price |
| 16:47 | 5,589 @ 7,348.07p |
| 16:35 | 766 @ 7,290.00p |
| 16:35 | 681 @ 7,290.00p |
| 16:35 | 151 @ 7,290.00p |
| 16:35 | 2,882 @ 7,290.00p |
You are here: research